Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice

Journal of Bone and Mineral Research

Volumn 26, Issue 8, 2011, Pages 1883-1890

  Ranch, Daniel ^a   Zhang, Martin Y H ^a   Portale, Anthony A ^a   Perwad, Farzana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1,25(OH)2D; FGF 23; MAPK; phosphate; XLH

Indexed keywords

BETA ACTIN; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; GENE PRODUCT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXYGENASE; PHOSPHATE; PROTEIN NPT2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; NPT2A GENE; PHOSPHATE METABOLISM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VITAMIN D METABOLISM; WILD TYPE;

ANIMALS; BENZAMIDES; BONE AND BONES; CALCIUM; DIPHENYLAMINE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PARATHYROID HORMONE; PHOSPHATES; RNA, MESSENGER; VITAMIN D;

EID: 79960636583     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.401     Document Type: Article

References (45)

1. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87: 4957-4960. (Pubitemid 35316332)
2. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348: 1656-1663. (Pubitemid 36459471)
3. Imel EA, Hui SL, Econs MJ,. FGF-23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007; 22: 520-526. (Pubitemid 47457428)
4. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38: 1310-1315. (Pubitemid 44646294)
5. Anonymous. A gene (PEX) with homologies with endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995; 11: 130-136.
6. Dixon PH, Christie PT, Wooding C, et al. Mutational analysis of PHEX gene in X-linked hypophosphatemia. J Clin Endocrinol Metab 1998. 83: 3615-3623. (Pubitemid 28500899)
7. Rowe PS, Oudet CL, Francis F, et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet. 1997; 6: 539-549. (Pubitemid 27142102)
8. Holm IA, Huang X, Kunkel LM,. Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet. 1997; 60: 790-797. (Pubitemid 27146486)
9. Eicher EM, Southard JL, Scriver CR, Glorieux FH,. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A. 1976; 73: 4667-4671. (Pubitemid 8013582)
10. Beck L, Soumounou Y, Martel J, et al. Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest. 1997; 99: 1200-1209. (Pubitemid 27142755)
11. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD,. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006; 291: E38-49. (Pubitemid 44035308)
12. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145: 3087-3094. (Pubitemid 38829975)
13. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-435. (Pubitemid 38787398)
14. Perwad F, Zhang MY, Tenenhouse HS, Portale AA,. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007; 293: F1577-1583. (Pubitemid 350085994)
15. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23: 421-432. (Pubitemid 39576657)
16. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444: 770-774. (Pubitemid 44949607)
17. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281: 6120-6123. (Pubitemid 43847540)
18. Lim CP, Jain N, Cao X,. Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene. 1998; 16: 2915-2926. (Pubitemid 28383276)
19. Guha M, O'Connell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood. 2001; 98: 1429-1439.
20. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N,. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem. 2002; 277: 28265-28270. (Pubitemid 34966781)
21. Farrow EG, Davis SI, Summers LJ, White KE,. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol. 2009; 20: 955-960.
22. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ,. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001; 60: 2079-2086. (Pubitemid 33070451)
23. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143: 3179-3182. (Pubitemid 34809892)
24. Bai XY, Miao D, Goltzman D, Karaplis AC,. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003; 278: 9843-9849. (Pubitemid 36800487)
25. Cohen P,. Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002; 1: 309-315. (Pubitemid 37361447)
26. Brown AP, Carlson TC, Loi CM, Graziano MJ,. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol. 2007; 59: 671-679. (Pubitemid 46295133)
27. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408: 297-315.
28. Sebolt-Leopold JS,. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res. 2008; 14: 3651-3656.
29. Barrett SD, Bridges AJ, Dudley DT, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008; 18: 6501-6504.
30. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE,. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone. 2005; 36: 971-977. (Pubitemid 40797997)
31. Madjdpour C, Bacic D, Kaissling B, Murer H, Biber J,. Segment-specific expression of sodium-phosphate cotransporters NaPi-IIa and -IIc and interacting proteins in mouse renal proximal tubules. Pflugers Arch. 2004; 448: 402-410. (Pubitemid 39006004)
32. Biber J, Stieger B, Stange G, Murer H,. Isolation of renal proximal tubular brush-border membranes. Nat Protoc. 2007; 2: 1356-1359. (Pubitemid 46952317)
33. Zhang MY, Wang X, Wang JT, et al. Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1alpha-hydroxylase gene expression in the proximal renal tubule. Endocrinology. 2002; 143: 587-595. (Pubitemid 34107213)
34. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA,. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005; 146: 5358-5364. (Pubitemid 41653049)
35. Azam N, Zhang MY, Wang X, Tenenhouse HS, Portale AA,. Disordered regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (hyp) mice. Endocrinology. 2003; 144: 3463-3468. (Pubitemid 36904423)
36. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD,. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003; 278: 37419-37426. (Pubitemid 37175262)
37. Tenenhouse HS, Jones G,. Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets. J Clin Invest. 1990; 85: 1450-1455. (Pubitemid 20176437)
38. Roy S, Martel J, Tenenhouse HS,. Growth hormone normalizes renal 1,25 dihydroxyvitamin D3-24-hydroxylase gene expression but not Na+-phosphate cotransporter (Npt2) mRNA in phosphate-deprived Hyp mice. J Bone Miner Res. 1997; 12: 1672-1680. (Pubitemid 27422368)
39. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004; 314: 409-414. (Pubitemid 38084732)
40. Tenenhouse HS, Martel J, Gauthier C, Segawa H, Miyamoto K,. Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol. 2003; 285: F1271-1278. (Pubitemid 37421062)
41. Kiebzak GM, Roos BA, Meyer RA Jr., Secondary hyperparathyroidism in X-linked hypophosphatemic mice. Endocrinology. 1982; 111: 650-652.
42. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117: 4003-4008. (Pubitemid 350224109)
43. Medici D, Razzaque MS, Deluca S, et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol. 2008; 182: 459-465.
44. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008; 23: 1509-1518.
45. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24: 1879-1888.